- Home
- OKUR vs CTMX Comparison
OKUR vs CTMX Comparison
Compare OKUR & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKUR
- CTMX
- Stock Information
- Founded
- OKUR 2011
- CTMX 2008
- Country
- OKUR United States
- CTMX United States
- Employees
- OKUR N/A
- CTMX N/A
- Industry
- OKUR
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- OKUR
- CTMX Health Care
- Exchange
- OKUR NYSE
- CTMX Nasdaq
- Market Cap
- OKUR 75.5M
- CTMX 85.3M
- IPO Year
- OKUR N/A
- CTMX 2015
- Fundamental
- Price
- OKUR $5.74
- CTMX $0.86
- Analyst Decision
- OKUR Strong Buy
- CTMX Buy
- Analyst Count
- OKUR 4
- CTMX 6
- Target Price
- OKUR $35.00
- CTMX $5.77
- AVG Volume (30 Days)
- OKUR 135.4K
- CTMX 1.0M
- Earning Date
- OKUR 02-14-2025
- CTMX 03-10-2025
- Dividend Yield
- OKUR N/A
- CTMX N/A
- EPS Growth
- OKUR N/A
- CTMX N/A
- EPS
- OKUR N/A
- CTMX 0.16
- Revenue
- OKUR N/A
- CTMX $126,617,000.00
- Revenue This Year
- OKUR N/A
- CTMX $22.55
- Revenue Next Year
- OKUR N/A
- CTMX N/A
- P/E Ratio
- OKUR N/A
- CTMX $5.31
- Revenue Growth
- OKUR N/A
- CTMX 33.66
- 52 Week Low
- OKUR $4.58
- CTMX $0.79
- 52 Week High
- OKUR $20.00
- CTMX $5.85
- Technical
- Relative Strength Index (RSI)
- OKUR N/A
- CTMX 43.26
- Support Level
- OKUR N/A
- CTMX $0.82
- Resistance Level
- OKUR N/A
- CTMX $0.92
- Average True Range (ATR)
- OKUR 0.00
- CTMX 0.06
- MACD
- OKUR 0.00
- CTMX 0.00
- Stochastic Oscillator
- OKUR 0.00
- CTMX 51.32
About OKUR ONKURE THERAPEUTICS INC
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.